Log In
BCIQ
Print this Print this
 

DecisionDx-Melanoma test

  Manage Alerts
Collapse Summary General Information
Company Castle Biosciences Inc.
DescriptionReal-time PCR test that analyzes the expression of 31 genes from formalin-fixed, paraffin-embedded (FFPE) biopsies or wide excisions of primary melanoma tumors
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsPredict metastatic risk in melanoma patients; Predict metastatic risk in stage I or II melanoma patients who have no sign of disease beyond the original tumor
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today